Summit Wealth Group LLC Co. Sells 21,449 Shares of Abbott Laboratories $ABT

Key Points

• Summit Wealth Group LLC cut its Abbott Laboratories stake by 91.4% in the fourth quarter, selling 21,449 shares and ending with 2,028 shares worth about $254,000.
• Abbott beat quarterly expectations with EPS of $1.15 versus $1.14 expected and revenue of $11.16 billion, up 7.8% year over year; it also reaffirmed guidance for FY2026 and Q2 2026.
• The company declared a quarterly dividend of $0.63 per share, implying an annualized payout of $2.52 and a yield of about 3.0%, while analysts currently rate the stock a consensus Moderate Buy.

Summit Wealth Group LLC Co. decreased its position in Abbott Laboratories (NYSE:ABT - Free Report) by 91.4% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,028 shares of the healthcare product maker's stock after selling 21,449 shares during the quarter. Summit Wealth Group LLC Co.'s holdings in Abbott Laboratories were worth $254,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in Abbott Laboratories by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker's stock valued at $21,995,501,000 after acquiring an additional 2,402,408 shares during the period. Capital International Investors lifted its holdings in Abbott Laboratories by 2.5% in the third quarter. Capital International Investors now owns 61,614,739 shares of the healthcare product maker's stock valued at $8,251,974,000 after acquiring an additional 1,478,076 shares during the period. Massachusetts Financial Services Co. MA lifted its holdings in Abbott Laboratories by 5.8% in the third quarter. Massachusetts Financial Services Co. MA now owns 15,096,907 shares of the healthcare product maker's stock valued at $2,022,080,000 after acquiring an additional 821,325 shares during the period. Invesco Ltd. lifted its holdings in Abbott Laboratories by 51.0% in the third quarter. Invesco Ltd. now owns 13,951,907 shares of the healthcare product maker's stock valued at $1,868,718,000 after acquiring an additional 4,713,135 shares during the period. Finally, Ameriprise Financial Inc. lifted its holdings in Abbott Laboratories by 3.8% in the third quarter. Ameriprise Financial Inc. now owns 13,500,829 shares of the healthcare product maker's stock valued at $1,804,050,000 after acquiring an additional 499,351 shares during the period. Institutional investors own 75.18% of the company's stock.

Abbott Laboratories Stock Up 1.2%

Shares of ABT opened at $84.80 on Friday. The business's 50 day moving average is $99.59 and its 200 day moving average is $113.55. The company has a market capitalization of $147.70 billion, a PE ratio of 23.75, a price-to-earnings-growth ratio of 1.40 and a beta of 0.65. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $139.06. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The company had revenue of $11.16 billion for the quarter, compared to the consensus estimate of $10.99 billion. During the same quarter last year, the company earned $1.09 EPS. The firm's quarterly revenue was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Research analysts expect that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a yield of 3.0%. Abbott Laboratories's payout ratio is presently 70.59%.

Insiders Place Their Bets

In other news, Director Daniel J. Starks acquired 10,000 shares of Abbott Laboratories stock in a transaction on Monday, April 27th. The shares were acquired at an average price of $92.65 per share, with a total value of $926,500.00. Following the purchase, the director directly owned 6,751,103 shares in the company, valued at $625,489,692.95. The trade was a 0.15% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Philip P. Boudreau acquired 2,200 shares of Abbott Laboratories stock in a transaction on Thursday, April 23rd. The stock was purchased at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the purchase, the chief financial officer owned 2,200 shares in the company, valued at approximately $201,300. The trade was a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last quarter, insiders have sold 3,055 shares of company stock worth $353,097. Insiders own 0.46% of the company's stock.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: TipRanks highlighted Abbott as one of three “Strong Buy” Dividend Aristocrat stocks, which can support the stock’s appeal for income-focused investors despite a high payout ratio. 3 ‘Strong Buy’ Dividend Aristocrat Stocks with 100%+ Payout Ratios, 5/14/26
• Neutral Sentiment: Jim Cramer called Abbott one of the “greatest American companies” while comparing the selloff to the 1999 market backdrop, a comment that may help sentiment but does not change fundamentals. Jim Cramer Compares the Current Selloff in Abbott Labs to the 1999 Market Environment
• Neutral Sentiment: Recent insider-trading coverage noted buying activity around Abbott, which can be viewed as a modest confidence signal but is not necessarily a major catalyst on its own. Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell (ABT)
• Negative Sentiment: Investor concerns remain centered on Abbott’s post-earnings weakness, with commentary pointing to Exact Sciences dilution, legal risks, and softer Diagnostics trends as reasons the shares have been pressured. Abbott Stock at 52-Week Low After Q1 Earnings: Book Profits or Hold?

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Wells Fargo & Company reduced their price target on Abbott Laboratories from $122.00 to $109.00 and set an "overweight" rating for the company in a research report on Friday, April 17th. Freedom Capital upgraded Abbott Laboratories from a "hold" rating to a "strong-buy" rating in a research report on Thursday, January 29th. Weiss Ratings cut Abbott Laboratories from a "hold (c)" rating to a "hold (c-)" rating in a research report on Friday, April 24th. UBS Group reduced their price target on Abbott Laboratories from $158.00 to $135.00 and set a "buy" rating for the company in a research report on Monday, April 20th. Finally, Jefferies Financial Group reduced their price target on Abbott Laboratories from $145.00 to $135.00 and set a "buy" rating for the company in a research report on Friday, April 17th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $119.43.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.